AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Zealand Pharma A/S
Video analysis: ZLDPF
All videosNo video analysis for this stock yet. Request one from our team.
News: ZLDPF
Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates
Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year ago.
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scientific Sessions in New Orleans.
Similar companies
-
ALK-Abelló A/S
AKBLF
·
Other OTC
Compare
-
Shanghai Junshi Biosciences Co., Ltd.
SHJBF
·
Other OTC
Compare
-
InnoCare Pharma Limited
INCPF
·
Other OTC
Compare
-
H. Lundbeck A/S
HLUBF
·
Other OTC
Compare
-
Laboratorios Farmaceuticos Rovi, S.A.
LABFF
·
Other OTC
Compare
-
Genscript Biotech Corporation
GNNSF
·
Other OTC
Compare